Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 78Neoplasms 69Prostatic Neoplasms 51Colorectal Neoplasms 45Lung Neoplasms 39Carcinoma, Non-Small-Cell Lung 28Hematologic Neoplasms 22Pancreatic Neoplasms 21Neoplasm Metastasis 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 15Ovarian Neoplasms 15Multiple Myeloma 15Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Motor Activity 11Leukemia, Myeloid, Acute 11Glioblastoma 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Gastrointestinal Neoplasms 9Colonic Neoplasms 9Melanoma 8Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Esophageal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8

Interventions

Pemetrexed 9Nivolumab 8Cisplatin 8Carboplatin 8pembrolizumab 7130-nm albumin-bound paclitaxel 7Gemcitabine 6padeliporfin 5durvalumab 5Paclitaxel 5Bevacizumab 5palbociclib 4napabucasin 4atezolizumab 4Irinotecan 4Fulvestrant 4Fluorouracil 4Drug Therapy 4Cyclophosphamide 4ribociclib 3osimertinib 3cobimetinib 3alectinib 3abemaciclib 3Trastuzumab 3Sunitinib 3Radiosurgery 3Mitomycin 3Docetaxel 3Cetuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Site × Standard of Care × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

Phase 2 Terminated
142 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡